This handout is for ulcerative colitis. Your care team identified this based on: bloody diarrhea ± urgency / tenesmus.
Other reasons your team may use this plan: chronic rectal bleeding / mucous in stool; severe flare with systemic toxicity (truelove-witts); elevated fecal calprotectin / crp.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| mesalamine_oral | 4-4.8 g PO daily (single dose preferred for adherence) | PO | daily | ACG 2025 — first-line for mild-moderate UC; high-dose preferred (≥3 g/day) |
| mesalamine_rectal | 1 g PR enema or 1 g suppository daily | PR | daily | Topical superior to oral for proctitis; combined topical+oral best for left-sided |
| sulfasalazine | 500 mg PO QID titrated to 4 g/day | PO | QID | Useful in UC + arthropathy; folate supplementation |
Plan: Ulcerative colitis — Truelove-Witts severity-driven induction + advanced therapy maintenance (ACG 2025 + AGA 2024 living + ECCO)
Use these zones to know what to do based on how you feel.
Call 911 or go to the nearest emergency room right away if you have:
Post-induction 8-12w; maintenance q3-6mo stable; flare urgent <1w; ASUC daily inpatient; post-colectomy surgical follow-up; CRC surveillance; preconception counselling
Guideline: 2025 ACG UC Guideline (Rubin) + AGA 2024 Living Guideline (updated 2025) + ECCO 2022 Therapeutics + 2024 EIM update + NICE NG130 (2025-2026) + LUCENT (mirikizumab) + TRUE NORTH (ozanimod) + ELEVATE UC 52/12 (etrasimod) + U-ACHIEVE/U-ACCOMPLISH (upadacitinib) + UNIFI (ustekinumab) + OCTAVE (tofacitinib) + ACT 1/2 (infliximab) + VARSITY